Drug intelligence / Profile preview

Ad5.ENVA.48 HIV-1 vaccine

Development stage: Phase 1
Lead developer: Johnson & Johnson
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The Ad5.ENVA.48 HIV-1 vaccine is a recombinant adenovirus type 5 (Ad5) vector vaccine designed to elicit immune responses against HIV-1. It contains a replication-defective Ad5 vector expressing HIV-1 envelope (Env) antigens, specifically the ENVA.48 variant. This vaccine is part of a class of adenovirus-vectored HIV vaccines that aim to induce cell-mediated immunity against HIV-1.

Targets

CXADR (Coxsackievirus and adenovirus receptor)MHC II (Major histocompatibility complex class II receptor)CD8A (CD8 alpha/beta Coreceptor)BCR-HIV-Env (HIV-1 envelope-specific B-cell receptor)MHC I (MHC class I})

Beyond the preview

Go deeper on Ad5.ENVA.48 HIV-1 vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ad5.ENVA.48 HIV-1 vaccine.

Explore the full profile